CBEA-ACannabielsoic acid A
The acid form of cannabielsoin, an oxidation artefact of acidic CBD, with no pharmacology of its own measured.
C₂₂H₃₀O₅
CAS 26674-02-2
- Family
- PhytocannabinoidMinor
- Origin
- Degradation product
- Molar mass
- 374.50 g/mol
Updated on
In plain terms
Cannabielsoic acid A is the acid form of cannabielsoin, a cannabinoid that forms by oxidation of acidic CBD (CBDA). It was isolated from hashish in 1974. Its own pharmacology has never been measured.
Receptors and activity
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of CBEA-A, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Cannabielsoic acid A belongs to the cannabielsoin family, recognisable by its dibenzofuran nucleus formed by closing a furan ring on the cannabidiol skeleton. Shani and Mechoulam described it as early as 1970 through a photo-oxidative cyclisation, then isolated it from hashish in 1974 together with its isomer B, which differs only in the position of the carboxyl (2 for A, 4 for B). It is an oxidation product of cannabidiolic acid; its decarboxylation gives cannabielsoin. No affinity for CB1 or CB2 has been measured for the acid form. The only pharmacology available in the family concerns cannabielsoin, a CB1 agonist on the cAMP pathway (EC50 3.7 µM) without β-arrestin recruitment (Haghdoost 2024), a profile that cannot be transposed to the acid. No animal or human data exist.
Key sources.
- Shani & Mechoulam 1970, J Chem Soc D: a new type of cannabinoid, synthesis of cannabielsoic acid A by photo-oxidative cyclisation (new tab)DOI 10.1039/c29700000273
- Shani & Mechoulam 1974, Tetrahedron 30:2437-2446: cannabielsoic acids, isolation and synthesis by oxidative cyclisation (new tab)DOI 10.1016/S0040-4020(01)97114-5
- Haghdoost et al. 2024, Biomedicines: cannabielsoin, a CBD oxidation product, biased CB1 agonist (new tab)PMID 39062125
- Yamamoto et al. 1991, Pharmacol Biochem Behav: cannabielsoin, a CBD metabolite in mammals (new tab)PMID 1806944
- Gul et al. 2023, Planta Med: validated GC-FID method for 20 cannabinoids (including CBEA) (new tab)PMID 36257598
- ElSohly & Slade 2005, Life Sci: CBE-type cannabinoids (CBEA-C5 A and B, CBEA-C3 B) (new tab)PMID 16199061
- Radwan et al. 2021, Molecules: inventory of cannabis cannabinoids (CBE type) (new tab)PMID 34066753
- PubChem CID 59444405: cannabielsoic acid A (new tab)
History
- Source
- Present in cannabis (hashish) as an oxidation product of cannabidiolic acid (CBDA).
Biosynthetic pathway
No enzyme is known. Cannabielsoic acids form by oxidative cyclisation of CBDA, which closes a furan ring and gives the family's dibenzofuran nucleus; Shani and Mechoulam achieved this type of cyclisation in the laboratory (1970, 1974). Decarboxylation leads to cannabielsoin.
Legal framework
- European Union
No EU instrument specific to the molecule; not named in the schedules of the 1961 and 1971 United Nations conventions.
- France
Not classified as a narcotic: cannabielsoic acid A is not named in the ANSM consolidated list (updated 26/06/2026). Its dibenzofuran nucleus is not the benzo[c]chromene nucleus of the generic class (ANSM decisions of 22/05/2024 and 03/06/2024), and it is not a tetrahydrocannabinol within the entry « Tétrahydrocannabinols, leurs esters, éthers, sels » (annex III since the ANSM decision of 06/02/2026). Not being a narcotic is not, in itself, an authorisation to sell. Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Phytocannabinoid › Minor
- Presence in the plant
Artefact: formed by oxidation, light, heat or solvent
- Chemistry
Type CBE · C5 side chain · acid form
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
No dedicated article.
References
- Shani & Mechoulam 1970, J Chem Soc D: a new type of cannabinoid, synthesis of cannabielsoic acid A by photo-oxidative cyclisation (new tab)DOI 10.1039/c29700000273
- Shani & Mechoulam 1974, Tetrahedron 30:2437-2446: cannabielsoic acids, isolation and synthesis by oxidative cyclisation (new tab)DOI 10.1016/S0040-4020(01)97114-5
- Haghdoost et al. 2024, Biomedicines: cannabielsoin, a CBD oxidation product, biased CB1 agonist (new tab)PMID 39062125
- Yamamoto et al. 1991, Pharmacol Biochem Behav: cannabielsoin, a CBD metabolite in mammals (new tab)PMID 1806944
- Gul et al. 2023, Planta Med: validated GC-FID method for 20 cannabinoids (including CBEA) (new tab)PMID 36257598
- ElSohly & Slade 2005, Life Sci: CBE-type cannabinoids (CBEA-C5 A and B, CBEA-C3 B) (new tab)PMID 16199061
- Radwan et al. 2021, Molecules: inventory of cannabis cannabinoids (CBE type) (new tab)PMID 34066753
- PubChem CID 59444405: cannabielsoic acid A (new tab)
Identifiers
Names
- Common name
- Cannabielsoic acid A
- IUPAC name
- (5aS,6S,9R,9aR)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5aH-dibenzofuran-2-carboxylic acid
- Other names
- CBEA-C5 A · CBEA-A
Identifiers
- Formula
- C₂₂H₃₀O₅
- CAS
- 26674-02-2
- PubChem CID
- 59444405(new tab)
- InChIKey
- OQCOBNKTUMOOHJ-RSGMMRJUSA-N
- SMILES
- CCCCCC1=
CC2= C([C@H] 3[C@@H] (CC[C@] ([C@H] 3O2) (C) O) C(= C) C) C(= C1C(= O) O) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.